New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 23, 2013
10:13 EDTDGXQuest Diagnostics gaps down, spikes lower, after earnings
The stock was last down over 6.5% which is off the lows of the session. The company reported earnings of $1.01 per share versus consensus of $1.02 for its Q4. It is guidance which is taking the shares down, which was reduced to a range of $4.35 to $4.55 for its fiscal year 2013 versus consensus of $4.81. At the current price of $57.66, support is at $57.11. a recent pivot low on the daily chart. Resistance is at $58, today's opening price.
News For DGX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 18, 2014
06:18 EDTDGXRedHill Biopharma acquires techonology from University of Minnesota
RedHill Biopharma (RDHL) has entered into a license agreement with the University of Minnesota to acquire the rights to a patented technology to support the development of a commercial diagnostic test for detection of Mycobacterium avium subspecies paratuberculosis bacterium. RedHill's Crohn's disease program RHB-104, currently undergoing a first Phase III study, is based on evidence that Crohn's disease is caused by MAP infection in susceptible patients. As part of development for RHB-104, RedHill is developing, in collaboration with Quest Diagnostics (DGX), a diagnostic test to aid in detecting the presence of MAP in whole blood. RedHill will pay the University of Minnesota a one-time upfront payment and an additional potential milestone payment for the licensed technology. A pre-submission meeting with the FDA to discuss the development path for the diagnostic test is scheduled for January 2015.
December 9, 2014
07:44 EDTDGXAmerican Association for Cancer Research to hold a symposium
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use